Brief: Isofol Announces Topline Results Of Phase III Agent Study

Isofol Medical AB (publ)

03/08/2022 14:33

Aug 3 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * DID NOT MEET PRIMARY OR KEY SECONDARY ENDPOINTS
    * SUB-GROUP ANALYSES, GENE EXPRESSION AND SAFETY DATA IS
EXPECTED
TO BE AVAILABLE IN FINAL STUDY REPORT IN Q4 2022

Source text for Eikon:  ID:nWkrbSNsJy 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))